329 related articles for article (PubMed ID: 26763733)
21. Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer.
Tardoski S; Ngo J; Gineyts E; Roux JP; Clézardin P; Melodelima D
Sci Rep; 2015 Nov; 5():16354. PubMed ID: 26578234
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
[TBL] [Abstract][Full Text] [Related]
23. Lipid Bilayer-Gated Mesoporous Silica Nanocarriers for Tumor-Targeted Delivery of Zoledronic Acid in Vivo.
Desai D; Zhang J; Sandholm J; Lehtimäki J; Grönroos T; Tuomela J; Rosenholm JM
Mol Pharm; 2017 Sep; 14(9):3218-3227. PubMed ID: 28737925
[TBL] [Abstract][Full Text] [Related]
24. Controlled delivery of zoledronate improved bone formation locally in vivo.
Gou W; Wang X; Peng J; Lu Q; Wang Y; Wang A; Guo Q; Gao X; Xu W; Lu S
PLoS One; 2014; 9(3):e91317. PubMed ID: 24618585
[TBL] [Abstract][Full Text] [Related]
25. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
26. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma.
Horie N; Murata H; Kimura S; Takeshita H; Sakabe T; Matsui T; Maekawa T; Kubo T; Fushiki S
Br J Cancer; 2007 Jan; 96(2):255-61. PubMed ID: 17242698
[TBL] [Abstract][Full Text] [Related]
27. Zoledronate can promote apoptosis and inhibit the proliferation of colorectal cancer cells.
Gao X; Jiang B; Zou S; Zhang T; Qi X; Jin L; Ge X; Tang SC; Hua D; Chen W
Tumour Biol; 2015 Jul; 36(7):5315-22. PubMed ID: 25682285
[TBL] [Abstract][Full Text] [Related]
28. Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells.
Fujita M; Tohi M; Sawada K; Yamamoto Y; Nakamura T; Yagami T; Yamamori M; Okamura N
Oncol Rep; 2012 May; 27(5):1371-6. PubMed ID: 22322451
[TBL] [Abstract][Full Text] [Related]
29. Bone-Targeted Mesoporous Silica Nanocarrier Anchored by Zoledronate for Cancer Bone Metastasis.
Sun W; Han Y; Li Z; Ge K; Zhang J
Langmuir; 2016 Sep; 32(36):9237-44. PubMed ID: 27531422
[TBL] [Abstract][Full Text] [Related]
30. Organic metal complexes based on zoledronate-calcium: a potential pDNA delivery system.
Li W; Xin X; Jing S; Zhang X; Chen K; Chen D; Hu H
J Mater Chem B; 2017 Feb; 5(8):1601-1610. PubMed ID: 32263932
[TBL] [Abstract][Full Text] [Related]
31. The combined use of Camellia sinensis and metronomic zoledronate in 4T1 mouse carcinoma against tumor growth and metastasis.
Luo KW; Yue GG; Ko CH; Gao S; Lee JK; Li G; Fung KP; Leung PC; Lau CB
Oncol Rep; 2015 Jul; 34(1):477-87. PubMed ID: 25998578
[TBL] [Abstract][Full Text] [Related]
32. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
[TBL] [Abstract][Full Text] [Related]
33. A bifunctional zoledronate sustained-release system in scaffold: Tumor therapy and bone repair.
Di W; Shuai Y; Bo W; Wei T; Jinpeng H; Qian G; Deng Y
Colloids Surf B Biointerfaces; 2023 Feb; 222():113064. PubMed ID: 36481508
[TBL] [Abstract][Full Text] [Related]
34. pH-sensitive polydopamine nanocapsules for cell imaging and drug delivery based on folate receptor targeting.
Cheng FF; Zhang JJ; Xu F; Hu LH; Abdel-Halim ES; Zhu JJ
J Biomed Nanotechnol; 2013 Jul; 9(7):1155-63. PubMed ID: 23909129
[TBL] [Abstract][Full Text] [Related]
35. CCN1, a candidate target for zoledronic acid treatment in breast cancer.
Espinoza I; Liu H; Busby R; Lupu R
Mol Cancer Ther; 2011 May; 10(5):732-41. PubMed ID: 21393426
[TBL] [Abstract][Full Text] [Related]
36. Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells.
Zhao Q; Liu J; Zhu W; Sun C; Di D; Zhang Y; Wang P; Wang Z; Wang S
Acta Biomater; 2015 Sep; 23():147-156. PubMed ID: 25985912
[TBL] [Abstract][Full Text] [Related]
37. Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA.
Massey AS; Pentlavalli S; Cunningham R; McCrudden CM; McErlean EM; Redpath P; Ali AA; Annett S; McBride JW; McCaffrey J; Robson T; Migaud ME; McCarthy HO
Mol Pharm; 2016 Apr; 13(4):1217-28. PubMed ID: 26954700
[TBL] [Abstract][Full Text] [Related]
38. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
[TBL] [Abstract][Full Text] [Related]
39. Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.
Porru M; Zappavigna S; Salzano G; Luce A; Stoppacciaro A; Balestrieri ML; Artuso S; Lusa S; De Rosa G; Leonetti C; Caraglia M
Oncotarget; 2014 Nov; 5(21):10446-59. PubMed ID: 25431953
[TBL] [Abstract][Full Text] [Related]
40. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.
Zarogoulidis K; Boutsikou E; Zarogoulidis P; Eleftheriadou E; Kontakiotis T; Lithoxopoulou H; Tzanakakis G; Kanakis I; Karamanos NK
Int J Cancer; 2009 Oct; 125(7):1705-9. PubMed ID: 19521984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
